- Home
- VRTX vs BMO Comparison
VRTX vs BMO Comparison
Compare VRTX & BMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRTX | BMO |
|---|---|---|
| Founded | 1989 | 1817 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Commercial Banks |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.8B | 127.2B |
| IPO Year | 2006 | 2014 |
Fundamental Metrics
Financial Performance| Metric | VRTX | BMO |
|---|---|---|
| Price | $507.48 | $165.86 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 32 | 15 |
| Target Price | ★ $571.39 | $166.26 |
| AVG Volume (30 Days) | ★ 821.4K | 399.0K |
| Earning Date | 11-02-2026 | 08-25-2026 |
| Dividend Yield | N/A | ★ 2.94% |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 8.33 | N/A |
| Revenue | ★ $2,488,652,000.00 | N/A |
| Revenue This Year | $10.39 | $8.26 |
| Revenue Next Year | $9.83 | $4.76 |
| P/E Ratio | $63.21 | ★ $17.46 |
| Revenue Growth | ★ 46.20 | N/A |
| 52 Week Low | $400.74 | $119.84 |
| 52 Week High | $560.25 | $187.22 |
Technical Indicators
Market Signals| Indicator | VRTX | BMO |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 35.31 |
| Support Level | $423.93 | $147.71 |
| Resistance Level | $554.04 | $177.35 |
| Average True Range (ATR) | 10.40 | 2.65 |
| MACD | -0.22 | -0.61 |
| Stochastic Oscillator | 67.92 | 4.04 |
Price Performance
Historical ComparisonAbout VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About BMO Bank Of Montreal
Bank of Montreal is a diversified financial services provider based in North America with over CAD 1.47 trillion in assets by the end of fiscal 2025. BMO operates four business segments: Canadian personal and commercial banking, US personal and commercial banking, wealth management, and capital markets. About 60% of BMO's earnings are generated in Canada and 40% in the US.